Constantin A Dasanu, Michael A Reale, Frank Bauer. Show Affiliations »
Abstract
Entities: Chemical Disease Species
Mesh： See more » Angiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy Protocols/therapeutic useBoronic Acids/administration & dosageBortezomibCombined Modality TherapyCyclin D1/physiologyDexamethasone/administration & dosageHematopoietic Stem Cell Transplantation/adverse effectsHumansImmunocompromised HostImmunosuppression/adverse effectsLenalidomideLymphoma, Mantle-Cell/pathologyMaleMelphalan/administration & dosageMiddle AgedMultiple Myeloma/drug therapyMultiple Myeloma/surgeryNeoplasm Proteins/physiologyNeoplasms, Second Primary/pathologyPyrazines/administration & dosageRituximabThalidomide/administration & dosageThalidomide/analogs & derivativesTransplantation, Autologous/adverse effects
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedBoronic AcidsCCND1 protein, humanNeoplasm ProteinsPyrazinesCyclin D1RituximabThalidomideBortezomibDexamethasoneLenalidomideMelphalan
Year: 2010 PMID： 20079532 DOI： 10.1016/j.leukres.2010.01.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156